21 CFR Part 11: (Un)Expected Added Value

Author(s)Ralph L. Dillon, Joseph F. Noferi, Esq., Daniel E. Worden

By Joseph F. Noferi, Esq., Ralph Dillon, and Daniel E. Worden, pp. 44-50. Implementing the ERES rule will do more than make your organization compliant with federal regulations. It will strengthen its intellectual property position for the information age.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 23 years ago

Article

Using a Model and Tools to Standardize the Preparation for a Preapproval Inspection

over 23 years ago

Article

Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar

over 23 years ago

Article

Outsourcing Outlook: Reaping the Benefits of E-Procurement

over 23 years ago

Article

The Immunogenicity of Therapeutic Proteins

over 23 years ago

Article

Analytical Advances: Calibration Management of Outsourced Calibrations

over 23 years ago

Article

High-Throughput Biopharmaceutical Drug Development: Meeting the Coming Challenge

over 23 years ago

Article

Inside Washington: Costs and Controls Challenge Manufacturers

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

21 CFR Part 11: (Un)Expected Added Value

Articles in this issue

Newsletter

Trending on BioPharm International

Biopharma’s Digital Hopes Versus Actual Implementation

Check Your Knowledge: Patient-Centric Care Through Oral Liquid Delivery

Check Your Knowledge (Answers): Patient-Centric Care Through Oral Liquid Delivery